DeepMed Research

JSC "VALENTA PHARM"

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Vespireit, Sustained-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Phase 4

Recruiting

Conditions: Vertigo
Autonomic Dysfunction

Interventions: Drug: Vespireit
Drug: Arlevert

First Posted Date: 2024-03-20

Last Posted Date: 2024-03-20

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 160

Registration Number: NCT06321341

Locations: 🇷🇺
Central Clinic LLC, Bryansk, Russian Federation
🇷🇺
State Budgetary Institution of Healthcare of the City of Moscow "V.P. Demikhov City Clinical Hospital of the Department of Healthcare of the City of Moscow", Moscow, Russian Federation
🇷🇺
Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of the city of Smolensk", Smolensk, Russian Federation

and more 1 locations

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Phase 1

Recruiting

Conditions: Cholecystitis

Interventions: Drug: 4-MUST, 1 tablet
Drug: 4-MUST, 3 tablets
Drug: 4-MUST, 2 tablets

First Posted Date: 2024-03-18

Last Posted Date: 2024-03-18

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 42

Registration Number: NCT06315387

Locations: 🇷🇺
Limited Liability Company "Medical Center Eco-Safety", St. Petersburg, Russian Federation

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

Phase 4

Recruiting

Conditions: Acute Respiratory Infection
Common Cold
Influenza, Human

Interventions: Drug: Placebo
Drug: Ingavirin®

First Posted Date: 2024-03-18

Last Posted Date: 2024-04-01

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 80

Registration Number: NCT06315400

Locations: 🇷🇺
GBOU VPO "Siberia State Medcial University" of Ministry of Health of Russian Federation, Tomsk, Russian Federation
🇷🇺
GBOU VPO "Rostov State Medical University" of Ministry of Health of Russian Federation, Rostov-na-Donu, Russian Federation
🇷🇺
GBOU VPO "Yaroslavl State Medical University" of Ministry of Health of Russian Federation, Yaroslavl, Russian Federation

Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

Not Applicable

Not yet recruiting

Conditions: Viral Infection COVID-19

Interventions: Drug: Aterixen

First Posted Date: 2023-10-24

Last Posted Date: 2024-03-29

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 36

Registration Number: NCT06096571

Locations: 🇷🇺
Limited Liability Company "Research Center Eco-Safety", Saint Petersburg,, Russian Federation

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Not Applicable

Recruiting

Conditions: Heartburn
Acid-dependent Diseases of the Gastrointestinal Tract
Symptomatic Treatment of Gastric and Duodenal Ulcers

Interventions: Drug: Antareit

First Posted Date: 2023-10-24

Last Posted Date: 2024-07-22

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 50

Registration Number: NCT06098742

Locations: 🇷🇺
Limited Liability Company "Research Center Eco-Safety", Saint Petersburg, Russian Federation
🇷🇺
Llc "Certa Clinic", Moscow, Russian Federation

A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

Phase 3

Completed

Conditions: Adjustment Disorders
Anxiety
Neurasthenia

Interventions: Drug: Ranquilon
Drug: Placebo

First Posted Date: 2022-10-19

Last Posted Date: 2023-07-27

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 220

Registration Number: NCT05586789

Locations: 🇷🇺
LLC "Aurora MedFort", Saint Petersburg, Russian Federation
🇷🇺
Limited Liability Company "Energy of Health", Saint Petersburg, Russian Federation
🇷🇺
Professors' Clinic LLC., Perm, Russian Federation

and more 7 locations

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Phase 3

Completed

Conditions: Pyoderma

Interventions: Drug: Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Drug: Hydroxymethylquinoxalindioxyde

First Posted Date: 2022-09-30

Last Posted Date: 2023-10-10

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 240

Registration Number: NCT05561816

Locations: 🇷🇺
Professor Gorbakov Clinic, LLC, Krasnogorsk, Russian Federation
🇷🇺
Yakusi Clinic, LLC, Saint Petersburg, Russian Federation
🇷🇺
Chelyabinsk Regional Clinical Dermatology and Venereology Dispensary, Chelyabinsk, Russian Federation

and more 7 locations

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

Not Applicable

Completed

Conditions: Influenza
Respiratory Viral Infection

Interventions: Drug: XC8

First Posted Date: 2022-09-28

Last Posted Date: 2023-10-10

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 24

Registration Number: NCT05558462

Locations: 🇷🇺
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Phase 3

Completed

Conditions: Influenza
Respiratory Viral Infection

Interventions: Drug: Placebo
Drug: XC221

First Posted Date: 2022-09-19

Last Posted Date: 2023-10-10

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 260

Registration Number: NCT05544916

Locations: 🇷🇺
Professors' Clinic LLC., Perm, Russian Federation
🇷🇺
Unimed-C Jsc, Moscow, Russian Federation
🇷🇺
State autonomous health care institution "Engels City Clinical Hospital No. 1", Engels, Russian Federation

and more 10 locations

Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Phase 1

Completed

Conditions: Infections

Interventions: Drug: Hydroxymethylquinoxalindioxyde

First Posted Date: 2022-08-17

Last Posted Date: 2023-08-21

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 16

Registration Number: NCT05505097

Locations: 🇷🇺
Limited Liability Company "X7 Clinical Research", Saint Petersburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy